

Table of Contents

CHAPTER 1. INTRODUCTION AND BACKGROUND

- § 1.9 Tangible personal property
- § 1.13 The boundaries of strict liability—Who is a seller or distributor?
- § 1.14 Component parts and raw material suppliers
- § 1.14.50 Manufacturer liability for designing to specifications *[New]*
- § 1.21 Successor liability for post-sale failure to warn

CHAPTER 2. THEORIES OF RECOVERY— MANUFACTURING DEFECT

- § 2.2 Manufacturing defects
- § 2.3 Overlapping theories
- § 2.4 Proof

CHAPTER 3. THEORIES OF RECOVERY— DESIGN DEFECT

- § 3.4 Risk-utility standard
- § 3.10 State of the art (feasible alternatives)—Minnesota
- § 3.13 Primary assumption of risk
- § 3.14 Foreseeable or intended use
- § 3.15 Causation
- § 3.18 Superseding cause
- § 3.20 The impact of compliance or noncompliance with product safety duties or regulations
- § 3.22 Negligent training *[New]*

CHAPTER 4. THEORIES OF LIABILITY— FAILURE TO WARN

- § 4.3 Adequacy of warnings
- § 4.6 Learned intermediaries
- § 4.11 Causation
- § 4.13 Warning not read
- § 4.16 A heeding presumption
- § 4.17 Post-sale obligations
- § 4.20 Duty to recall or retrofit

CHAPTER 5. BREACH OF WARRANTY *[New]*

I. INTRODUCTION

§ 5.0 Introduction

II. EXPRESS WARRANTY

- § 5.1 Express warranty generally
- § 5.2 Representation of fact
- § 5.3 Basis of the bargain
- § 5.4 Buyer must suffer a cognizable injury

III. IMPLIED WARRANTY OF MERCHANTABILITY

- § 5.5 Generally
- § 5.6 Sale of goods
- § 5.7 Seller is a merchant with respect to goods of that kind
- § 5.8 Sophisticated buyer—Effect on implied warranty of merchantability
- § 5.9 Fitness for ordinary purposes
- § 5.10 Other merchantability standards

IV. IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE

- § 5.11 Generally
- § 5.12 The seller's knowledge of the buyer's particular purpose
- § 5.13 The seller's knowledge of the buyer's reliance
- § 5.14 The buyer's actual reliance on the seller

V. BREACH OF WARRANTY

§ 5.15 Breach of Warranty—When does it occur?

VI. WHICH WARRANTY THEORY TO PLEAD?

- § 5.16 Generally
- § 5.17 Implied warranty of merchantability
- § 5.18 Express warranty
- § 5.19 Implied warranty of fitness for a particular purpose

VII. TO WHOM DOES THE WARRANTY EXTEND?—THIRD-PARTY BENEFICIARIES—PRIVITY

- § 5.20 Generally
- § 5.21 U.C.C. § 2-318—Horizontal privity
- § 5.22 Vertical privity
 - § 5.22.10 Vertical privity and express warranty
 - § 5.22.20 Vertical privity and implied warranty of fitness for a particular purpose
 - § 5.22.30 Vertical privity and implied warranty of merchantability

TABLE OF CONTENTS

- § 5.22.40 Vertical privity and claims for economic loss
- § 5.22.50 Vertical privity and revocation of acceptance
- § 5.23 Time limits, first buyer limits on warranty coverage
- § 5.24 Warranty liability of successor corporations, parent corporations

VIII. THE REQUIREMENT OF NOTICE OF BREACH

- § 5.25 Generally
- § 5.26 Burden of pleading notice
- § 5.27 Timeliness of the notice
- § 5.28 Sufficiency of the notice
- § 5.29 Notice to whom?

IX. DISCLAIMERS AND LIMITATIONS OF REMEDIES

- § 5.30 Generally
- § 5.31 Disclaimers of express warranties
- § 5.32 Disclaimers of oral express warranties
- § 5.33 Disclaimers of implied warranties—U.C.C. § 2-316
- § 5.33.30 The safe harbor of subsection (2)
- § 5.33.70 The exceptions of subsection (3)
- § 5.34 Unconscionability
- § 5.35 Limitations of remedies
- § 5.36 Anti-disclaimer law
- § 5.36.30 Magnuson-Moss Warranty Act
- § 5.36.70 Minnesota Consumer Protection Law
- § 5.37 Effect of disclaimers or limitations on third party beneficiaries

X. INDEMNIFICATION

- § 5.38 Indemnification

XI. NEW U.C.C. PROVISIONS

- § 5.39 Generally
- § 5.40 Express warranty
- § 5.41 Implied warranty of merchantability
- § 5.42 Implied warranty of fitness for a particular purpose
- § 5.43 To whom does the warranty extend?—Privity
- § 5.44 Notice of breach
- § 5.45 Disclaimers and limitations of remedies
- § 5.46 Unconscionability

XII. CONCLUSION

- § 5.47 Conclusion

**CHAPTER 6. THEORIES OF
RECOVERY—MISREPRESENTATION**
[New]

- § 6.1 Introduction
- § 6.2 Representation of fact
- § 6.3 Representation must be false
- § 6.4 Representation must be material
- § 6.5 Plaintiff must justifiably rely on representation
- § 6.6 Intentional misrepresentation—Defendant’s intent to deceive
- § 6.7 Reckless misrepresentation—Defendant’s state of mind
- § 6.8 Negligent misrepresentation—Standard of reasonable care
- § 6.9 Pecuniary loss limitation—Limited duty to act with reasonable care
- § 6.10 Pleading fraud with particularity
- § 6.11 Statutory consumer fraud claims—Generally
- § 6.12 Private Attorney General Statute—Requirement of public benefit
- § 6.13 Consumer Fraud Act
- § 6.14 Unlawful Trade Practices Act
- § 6.15 False Advertising Statute
- § 6.16 Deceptive Trade Practices Act
- § 6.17 Defenses—Contributory negligence
- § 6.18 Plaintiff’s duty to mitigate damages
- § 6.19 Damages—Minnesota’s “Out-of-Pocket” Rule
- § 6.20 Exceptions to the “Out-of-Pocket” Rule
- § 6.21 Attorney’s fees and other costs
- § 6.22 Conclusion

CHAPTER 7. COMPARATIVE FAULT

- § 7.11 Motorcycle helmet and seat belt evidence
- § 7.12 Joint and several liability and loss reallocation
- § 7.13 Joint and several liability: the 2003 Amendment
- § 7.15 The impact of employer liability on fault comparisons and contribution *[New]*

CHAPTER 8. DEFENSES

- § 8.2 Statute of limitations—Negligence—§ 541.05, subd. 1(5)
- § 8.3 Statute of limitations—Strict liability—§ 541.05, subd. 2
- § 8.4 Statute of limitations—Breach of warranty—§ 336.2-725
- § 8.6 Statute of limitations and repose—Improvements to real property and products liability cases—§ 541.051
- § 8.6.25 Continuing violation doctrine *[New]*
- § 8.6.50 Statute of limitations—Breach of warranty—§ 541.051 *[New]*
- § 8.7 Statute of limitations—Wrongful death—§ 573.02, subd. 1
- § 8.75 Statute of limitations—Wrongful death—§ 573.02—Asbestos cases *[New]*
- § 8.9 Tolling statutes of limitation—Fraudulent concealment
- § 8.13 The seller’s exception statute—§ 544.41

TABLE OF CONTENTS

CHAPTER 9. PREEMPTION [New]

- § 9.1 Introduction
- § 9.2 Background and general principles
- § 9.3 Medical devices—Generally
- § 9.4 Medical device preemption—Early developments
 - § 9.4.30 *Medtronic v. Lohr*
 - § 9.4.70 *Buckman v. Plaintiffs' Legal Committee*
- § 9.5 Medical device preemption—Post-*Lohr*
- § 9.6 Medical device preemption—*Riegel v. Medtronic, Inc.*
- § 9.7 Medical device preemption—Post-*Riegel*
- § 9.8 Type of claim—Generally
 - § 9.8.10 Manufacturing defect
 - § 9.8.20 Design defect
 - § 9.8.30 Inadequate warnings and labeling
 - § 9.8.40 Breach of warranty
 - § 9.8.50 Fraud and other deceptive trade practices
 - § 9.8.60 Medical monitoring
- § 9.9 The “narrow gap” between *Riegel* and *Buckman*—Parallel claims
- § 9.10 Medical device preemption—PMA supplement
- § 9.11 Medical device preemption—Investigational device exemption (IDE)
- § 9.12 Prescription drugs—Generally
- § 9.13 Prescription drugs—Labelling and warnings—*Wyeth v. Levine* and *Merck Sharp & Dohme Corp. v. Albrecht [Retitled]*
- § 9.14 Prescription drugs—Brand-name manufacturers’ liability for harms caused by generic drugs
- § 9.15 Generic drugs—Labelling and warnings—*PLIVA v. Mensing*
- § 9.16 Drugs—Design defects
- § 9.17 Over-the-counter drugs
- § 9.18 Children’s vaccines
- § 9.19 Food products [*Reserved*]
- § 9.20 Tobacco products
- § 9.21 Motor vehicles
- § 9.22 Hazardous and toxic products—Generally
 - § 9.22.25 Pesticides (FIFRA)
 - § 9.22.50 Federal Hazardous Substances Act
 - § 9.22.75 Animal Virus, Serum, Toxin and Analogous Products Act (VSTA)
- § 9.23 Consumer Product Safety Act
- § 9.24 Federal Boat Safety Act
- § 9.25 Aviation safety
- § 9.26 Cell phones
- § 9.27 Practice considerations—Pleading
- § 9.28 Summary judgment
- § 9.29 Discovery
- § 9.30 Evidentiary issues

CHAPTER 10. DISCOVERY

- § 10.1 Introduction

- § 10.2 Scope
- § 10.5 Work product
- § 10.6 Attorney-client privilege
- § 10.7 Statements
- § 10.9 Document requests
- § 10.10 Physical and mental exams
- § 10.11 Medical records
- § 10.12 Inspection and testing
- § 10.13 Depositions
- § 10.14 Depositions—Corporate representatives
- § 10.15 Protective orders
- § 10.16 Mass torts, class actions and consolidated discovery

CHAPTER 11. EXPERTS

- § 11.1 Introduction
- § 11.2 Rule 702 requirements—Generally
- § 11.3 Expert testimony required
- § 11.4 Qualification
- § 11.5 Foundation
- § 11.6 Scientific and technical evidence—*The Frye* general acceptance test
- § 11.7 Scientific and technical evidence—*Daubert* and its progeny
- § 11.8 Scientific and technical evidence—*Daubert* and its progeny—Alternative feasible design and testing
- § 11.9 Scientific and technical evidence—*Daubert* and its progeny—Publication, peer review and potential rate of error
- § 11.10 Scientific and technical evidence—*Daubert* and its progeny—Elimination of other causes
- § 11.11 Scientific and technical evidence—*Daubert* and its progeny—Litigation-related expertise or research
- § 11.12 Scientific and technical evidence—*Daubert* and its progeny—Connection between opinion and facts (analytical gap)
- § 11.13 Scientific and technical evidence—Minnesota’s *Frye-Mack* standard
- § 11.14 Scientific and technical evidence—*Frye-Mack v. Daubert*—Practical implications
- § 11.17 The expert’s role in product liability litigation—Generally
- § 11.19 The expert’s role in product liability litigation—Discovery and deposition—Federal court
- § 11.20 The expert’s role in product liability litigation—Discovery and deposition—Minnesota state court
- § 11.21 The expert’s role in product liability litigation—Discovery and deposition—Consulting experts
- § 11.23 The expert’s role in product liability litigation—Motions and Rule 104 hearings—Federal court

CHAPTER 12. EVIDENTIARY ISSUES

- § 12.2 Spoliation—Generally
- § 12.3 Spoliation—Notice
- § 12.4 Spoliation—Sanctions
- § 12.5 Spoliation—Practice points
- § 12.6 Product identification

TABLE OF CONTENTS

- § 12.7 Industry custom and standards
- § 12.8 Subsequent remedial measures
- § 12.9 Other accidents, occurrences and lawsuits
- § 12.10 Public records and reports of investigations

CHAPTER 13. DAMAGES

- § 13.1 Introduction
- § 13.3 Personal physical injury—Medical expenses
- § 13.5 Personal physical injury—Loss of consortium
- § 13.8 Personal physical injury—Collateral source deductions
- § 13.9 Personal physical injury—Emotional distress
- § 13.12 Personal physical injury—Medical monitoring
- § 13.13 Wrongful death
- § 13.14 Property damage
- § 13.15 Economic loss
- § 13.19 Punitive damages—Clear and convincing evidence standard
- § 13.21 Punitive damages—Constitutional limitations
- § 13.22 Punitive damages—Practice considerations
- § 13.23 Attorney’s fees

CHAPTER 14. SETTLEMENT

- § 14.2 Settlement agreements and releases—Generally
- § 14.3 Settlement agreements and releases—*Pierringer* releases
- § 14.4 Settlement agreements and releases—*Mary Carter* agreements
- § 14.6 Structured settlements—Generally
- § 14.7 Structured settlements—Transfer of payments

CHAPTER 15. CONSOLIDATION AND CLASS ACTIONS

- § 15.3 Multidistrict litigation
- § 15.4 Class actions—Generally
- § 15.8 Class actions—Rule 23(a) prerequisites—Commonality
- § 15.9 Class actions—Rule 23(a) prerequisites—Typicality
- § 15.10 Class actions—Rule 23(a) prerequisites—Adequacy of representation
- § 15.12 Class actions—Rule 23(b)—Rule 23(b)(1) mandatory class actions
- § 15.13 Class actions—Rule 23(b)—Rule 23(b)(2) equitable relief and medical monitoring
- § 15.15 Class actions—Rule 23(b)—Rule 23(b)(3) opt-out class actions—Predominance of individual issues of law
- § 15.16 Class actions—Rule 23(b)—Rule 23(b)(3) opt-out class actions—Predominance of individual issues of fact
- § 15.17 Class actions—Rule 23(b)—Rule 23(b)(3) opt-out class actions—Superiority
- § 15.18 Class actions—Rule 23(c)(4) subclasses and issues classes
- § 15.19 Class actions—Settlement classes
- § 15.20 Class actions—Class Action Fairness Act—Generally
- § 15.21 Class actions—Class Action Fairness Act—Federal jurisdiction
- § 15.22 Class actions—Class Action Fairness Act—Mass actions

- § 15.23 Class actions—Class Action Fairness Act—Removal
- § 15.25 Class actions—Minnesota state court class actions

CHAPTER 16. PRESCRIPTION DRUGS, DEVICES AND BIOLOGICS

- § 16.3 Unavoidably unsafe products—Minnesota’s risk/utility balancing test
- § 16.5 The learned intermediary doctrine—Generally
- § 16.6 The learned intermediary doctrine—Adequate warnings
- § 16.7 The learned intermediary doctrine—Intermediary’s knowledge and causation
- § 16.8 The learned intermediary doctrine—Exceptions—Generally
- § 16.10 The learned intermediary doctrine—Exceptions—Prescription contraceptives
- § 16.11 The learned intermediary doctrine—Exceptions—FDA-required warnings
- § 16.12 The learned intermediary doctrine—Exceptions—Consumer directed marketing
- § 16.15 The learned intermediary doctrine—Exceptions—Off-label use
- § 16.17 Causation—Expert testimony
- § 16.18 Causation—General and specific causation
- § 16.19 Causation—General and specific causation—Epidemiological and toxicological evidence
- § 16.20 Causation—General and specific causation—Differential diagnosis
- § 16.21 Legislative enactments—Minnesota blood shield statute
- § 16.22 Legislative enactments—National Childhood Vaccine Injury Act
- § 16.23 Legislative enactments—Biomaterials Access Assurance Act

CHAPTER 17. CONFLICT OF LAWS [New]

- § 17.1 Introduction
- § 17.2 Actual conflict
- § 17.3 Choice-influencing considerations
- § 17.4 Predictability of results
- § 17.5 Maintenance of interstate order
- § 17.6 Simplification of the judicial task
- § 17.7 Advancement of the forum’s governmental interests
- § 17.8 Application of the better rule of law
- § 17.9 Statutes of limitations
- § 17.10 Pre-Uniform Conflict of Laws—Limitations Act
- § 17.11 Uniform Conflict of Laws—Limitations Act
- § 17.12 Diversity cases

Appendices

Appendix A. Restatement of the Law (3d) Torts: Products Liability

Appendix B. Minnesota Products Liability Pattern Jury Instructions

Table of Laws and Rules

TABLE OF CONTENTS

Table of Cases

Index